Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-650 (infliximab) in IVIG-refractory Kawasaki disease
NCT01596335Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- May 2012
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Kawasaki disease (KD), sponsored by Mitsubishi Tanabe Pharma. Started May 2012; status: completed.
02
Drugs
infliximab
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on NCT01596335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01596335.